FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 60916

Company■ Unclear/unknown

Phase 3 results posted: A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia — Biosplice Therapeutics, Inc.

KINDCompany
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-01 12:00 UTC
LAST UPDATE2026-10-01 12:00 UTC
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

Completed alopecia Phase 3 results could matter for a private sponsor, with no efficacy detail provided.

Alopecia trial results, limited public relevance
CATALYST TO WATCH

Data publication or partnership news

MAIN RISK

Results may be inconclusive

FULL DISPATCH

Sponsor: Biosplice Therapeutics, Inc.; Status: Completed; Conditions: Androgenetic Alopecia; Interventions: Topical SM04554 0.15% solution, Topical SM04554 0.25% solution, Topical vehicle solution; Enrollment: 675 (actual); First posted: 2018-11-15; Results posted: 2026-10-01; NCT: NCT03742518

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01clinicaltrialsclinicaltrials.gov · PRIMARY2026-10-01 12:00 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.